Status:
COMPLETED
Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
Lead Sponsor:
Ferring Pharmaceuticals
Conditions:
Crohn's Disease
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to prospectively evaluate a scoring system to predict a mild course of disease in patients newly diagnosed with Crohn's disease.
Eligibility Criteria
Inclusion
- All patients with Crohn's disease who
- have been newly diagnosed (initial diagnosis not more than 6 weeks previously) and
- are as yet untreated (permitted medications are a maximum of 10 days of 5-aminosalicylates (5-ASA) or glucocorticosteroids and antibiotics for non-intestinal indications) and
- have consented to the documentation of their patient data and
- agree to the up to 5-year documentation of the course of disease
Exclusion
- Pre-treatment with 5-ASA \> 10 days
- Treatment with steroids \> 10 days
- Treatment with antibiotics, immunosuppressants or biological agents \> 10 days
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
216 Patients enrolled
Trial Details
Trial ID
NCT02193048
Start Date
September 1 2014
End Date
December 31 2021
Last Update
May 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational site (there may be other sites in this country)
Altenholz, Germany